Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe

por de With, M., Sadlon, A., Cecchin, E., Haufroid, V., Thomas, F., Joerger, M., van Schaik, R.H.N., Mathijssen, R.H.J., Largiadèr, C.R.
Publicado 2023

A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients

por Andrews, L. M., Hesselink, D. A., van Schaik, R. H. N., van Gelder, T., de Fijter, J. W., Lloberas, N., Elens, L., Moes, D. J. A. R., de Winter, B. C. M.
Publicado 2019

Policy and Practice Review: A First Guideline on the Use of Pharmacogenetics in Clinical Psychiatric Practice

por van Westrhenen, R., van Schaik, R. H. N., van Gelder, T., Birkenhager, T. K., Bakker, P. R., Houwink, E. J. F., Bet, P. M., Hoogendijk, W. J. G., van Weelden-Hulshof, M. J. M.
Publicado 2021

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment

por Beelen, K., Opdam, M., Severson, T. M., Koornstra, R. H. T., Vincent, A. D., Hauptmann, M., van Schaik, R. H. N., Berns, E. M. J. J., Vermorken, J. B., van Diest, P. J., Linn, S. C.
Publicado 2013

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer

por Lammers, L A, Mathijssen, R H J, van Gelder, T, Bijl, M J, de Graan, A-J M, Seynaeve, C, van Fessem, M A, Berns, E M, Vulto, A G, van Schaik, R H N
Publicado 2010